1. Monk B, et al. KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab 1 chemotherapy vs placebo 1 chemotherapy for first-line treatment of persistent, recurrent, or...
Colombo N et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: randomized, double-blind, phase 3 KEYNOTE-826 study. ESMO Congress 2021, Abstract LBA2...
1. Monk B, et al. KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab 1 chemotherapy vs placebo 1 chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. 2023 ASCO, abstract 5500. 2. Chung HC, et...
[1]康方生物官网:网页链接 [2]2022 ASCO Annual Meeting:A Study of AK104 (an Anti-PD1 and Anti-CTLA4 Bispecific Antibody) combined with standard therapy for the first-line treatment of recurrent or metastatic cervical cancer(R/M CC). [3]康方生物自愿公告:卡度尼利(PD-1/CTLA-4双抗,AK104)...
KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.121173111
The median overall survival (OS) shown with this treatment strategy in the study was 28.6 months vs 16.5 months with the placebo control. Moreover, an OS benefit was shown regardless PD-L1 expression level. The median progression-free survival observed with pembrolizumab plus chemotherapy with or...
Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 ... C Langer,SM Gaddgeel,H Borghaei,... - 《Annals of Oncology》 被引量: 11发表: 2016年 LBA49Updated results from KEYNOTE-021 cohort G: A ...
1. Monk B, et al. KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab 1 chemotherapy vs placebo 1 chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. 2023 ASCO, abstract 5500. ...
Colombo N et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: randomized, double-blind, phase 3 KEYNOTE-826 study. ESMO Congress 2021, Abstract LBA2 (来源:《肿瘤瞭望》编辑部) ...
Colombo N et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: randomized, double-blind, phase 3 KEYNOTE-826 study. ESMO Congress 2021, Abstract LBA2 版权声明 凡署名原创的文章版权属《肿瘤瞭望》所有。欢迎个人转发分享。其他任...